Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-NYM032
- Development stage
- Phase 3
- Lead developer
- Norroy Bioscience
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**68Ga-NYM032 is a small-molecule radiopharmaceutical designed for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions, primarily in patients with prostate cancer.** It acts as a PSMA-targeting radiotracer, enabling sensitive and specific detection of prostate cancer lesions, including osseous and lymph node metastases. The compound is labeled with gallium-68 for diagnostic PET/CT imaging and has also been evaluated in theranostic applications paired with lutetium-177 for potential therapeutic use. Preclinical and early clinical studies have shown that 68Ga-NYM032 demonstrates high uptake in PSMA-expressing tumors, favorable safety profile, and promising diagnostic performance comparable or superior to existing agents such as 68Ga-PSMA617[1][2][3][4]. The drug was initially developed by Norroy Bioscience.
- Brand names
- gallium ga-68-NYM032
- Other names
- 68GaNYM032Gallium [68Ga]-NYM032 injection
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 68Ga-NYM032.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-NYM032.